Guangfeng Wang
About
In The Last Decade
Guangfeng Wang
207 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Electrical and Electronic Engineering 4.1k
- Molecular Biology 2.6k
- Materials Chemistry 2.4k
- Electrochemistry 2.2k
- Biomedical Engineering 1.7k
Countries citing papers authored by Guangfeng Wang
This map shows the geographic impact of Guangfeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangfeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangfeng Wang more than expected).
Fields of papers citing papers by Guangfeng Wang
This network shows the impact of papers produced by Guangfeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangfeng Wang. The network helps show where Guangfeng Wang may publish in the future.
Co-authorship network of co-authors of Guangfeng Wang
This figure shows the co-authorship network connecting the top 25 collaborators of Guangfeng Wang. A scholar is included among the top collaborators of Guangfeng Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangfeng Wang. Guangfeng Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 3 | |
| 3 | 0 | |
| 4 | 7 | |
| 5 | 0 | |
| 6 | 0 | |
| 7 | 1 | |
| 8 | 6 | |
| 9 | 1 | |
| 10 | 23 | |
| 11 | 4 | |
| 12 | 1 | |
| 13 | 26 | |
| 14 | 33 | |
| 15 | 8 | |
| 16 | 23 | |
| 17 | 49 | |
| 18 | In vivo efficacy of AT-101, an orally active pan Bcl-2 family protein inhibitor in combination with docetaxel or erlotinib for non small cell lung cancer therapy | 1 |
| 19 | 24 | |
| 20 | 34 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.